SCHEMBL930968

SCHEMBL930968

CN1CCN(C)CC(C)(N)C1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.33
OPRM1 P35372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13576365 0.87
Hydrochloric Acid SCHEMBL30516243 0.84
SCHEMBL12457880 0.82
SCHEMBL18911774 0.82
SCHEMBL12457631 0.82
Hydrochloric Acid SCHEMBL5531798 0.80
SCHEMBL7888522 0.78
SCHEMBL12457874 0.78
Hydrochloric Acid SCHEMBL19747200 0.76 USP2 (0.34) DRD4OPRM1
SCHEMBL22253844 0.76 OPRM1 (0.32) DRD4OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220073735-A1 LIQUIDS Borchers Catalyst (UK) Limited (GB) 2022-03-10 US claimed
EP-3818101-A1 LIQUIDS Borchers Catalyst (UK) Limited (GB) 2021-05-12 EP claimed
CN-112739758-A Liquid, method for producing the same and use thereof 博奇斯催化剂(英国)有限公司 2021-04-30 CN claimed
EP-3307941-B1 OXIDATIVE METHOD CATEXEL TECH LIMITED (GB) 2021-03-24 EP claimed
US-10882745-B2 Oxidative method CATEXEL TECHNOLOGIES LIMITED (GB) 2021-01-05 US claimed
CN-107709533-B Oxidation process 卡特克塞尔科技有限公司 2020-09-18 CN claimed
WO-2020008203-A1 LIQUIDS CATEXEL LIMITED (GB) 2020-01-09 WO claimed
US-10457831-B2 Oxidatively curable coating composition CATEXEL LIMITED (GB) 2019-10-29 US claimed
US-20180186634-A1 OXIDATIVE METHOD CATEXEL B.V. (NL) 2018-07-05 US claimed
EP-3307941-A1 OXIDATIVE METHOD Catexel Technologies Limited (GB) 2018-04-18 EP claimed
EP-2954014-B1 OXIDATIVELY CURABLE COATING COMPOSITION CATEXEL LTD (GB) 2017-11-08 EP claimed
WO-2016198891-A1 OXIDATIVE METHOD CHEMSENTI LIMITED (GB) 2016-12-15 WO claimed
EP-2954014-A1 OXIDATIVELY CURABLE COATING COMPOSITION Catexel Limited (GB) 2015-12-16 EP claimed
US-20150337163-A1 OXIDATIVELY CURABLE COATING COMPOSITION CATEXEL LIMITED (GB) 2015-11-26 US claimed
WO-2014122434-A1 OXIDATIVELY CURABLE COATING COMPOSITION CATEXEL LIMITED (GB) 2014-08-14 WO claimed
EP-1280794-B1 DIAZACYCLOALKANE DERIVATIVES AS BLEACH CATALYST AND COMPOSITION AND METHOD FOR BLEACHING A SUBSTRATE UNILEVER PLC (GB) 2006-07-05 EP claimed
US-20020049148-A1 Bleach catalyst and composition and method for bleaching a substrate UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2002-04-25 US claimed
EP-4077464-B1 FREE RADICAL POLYMERIZABLE ADHESION-PROMOTING INTERLAYER COMPOSITIONS AND METHODS OF USE PRC DESOTO INT INC (US) 2026-04-29 EP disclosed
US-6537959-B2 Diazacycloalkanes, i.e., 1,4,6-trimethyl-6-(n-(pyridin-2-ylmethyl)-N-methylamino)-1,4 -diazacycloheptane; ligands in manganese, iron and cobalt transition metal complexes. UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2003-03-25 US disclosed
US-20020049148-A1 Bleach catalyst and composition and method for bleaching a substrate UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10882745-B2 Oxidative method CAT, LPO, GPX4 DRD4 1652/4885OPRM1 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.